alpha-casozepine

What Is Alpha-Casozepine?

Alpha-casozepine is a bioactive decapeptide derived from the enzymatic digestion of bovine αs1-casein, the primary protein in cow's milk. When casein is broken down by the digestive enzyme trypsin, it releases this specific peptide fragment, which has been shown to exert calming and anxiolytic-like effects across multiple species including rats, cats, horses, and dogs. It is the active ingredient in the commercially available veterinary product Zylkene (Vétoquinol), which has been available in veterinary practice for several decades and represents one of the most studied nutritional supplements for canine anxiety.

Its name is not coincidental: "casozepine" reflects its structural and functional resemblance to the benzodiazepine class of anxiolytic drugs, a resemblance that is both its most interesting pharmacological feature and the source of significant ongoing scientific debate.

How Alpha-Casozepine Works: A Fascinating and Incompletely Understood Mechanism

Alpha-casozepine exerts its calming effect by binding at the benzodiazepine binding site of the GABAA receptor in the brain. GABA (gamma-aminobutyric acid) is the central nervous system's primary inhibitory neurotransmitter. It reduces neuronal excitability and promotes a calming state. Benzodiazepines (such as diazepam/Valium) work by binding to a specific modulatory site on the GABAA receptor, enhancing its response to GABA and producing sedation, anxiolysis, and muscle relaxation. Alpha-casozepine appears to work through the same binding site, though with importantly different properties.

This mechanism was confirmed in a 2022 study using a rat anxiety model. Benoit et al. demonstrated that blocking the benzodiazepine binding site on GABAA receptors with the antagonist flumazenil completely abolished the anxiolytic-like properties of a casein hydrolysate containing alpha-casozepine, demonstrating that the benzodiazepine site is responsible for its anxiolytic effects. Importantly, the study also confirmed that the vagus nerve played no role in this mechanism, ruling out a gut-brain signaling pathway and pointing specifically to central nervous system activity. (Benoit et al., 2022)

The in vitro / in vivo paradox

The pharmacology of alpha-casozepine includes a striking and as yet incompletely explained anomaly. In laboratory (in vitro) conditions, alpha-casozepine demonstrated approximately 1,000 times lower binding affinity for the GABAA benzodiazepine site compared to diazepam, suggesting it should be far weaker. Yet in living animals (in vivo), it demonstrated approximately 10 times greater affinity than diazepam in the same system. This dramatic reversal between test tube and living organism is not yet fully explained, but has been attributed to the possible potentiating influence of neurosteroids - compounds synthesized within the brain itself that modulate GABAA receptor sensitivity - or other factors present in the intact central nervous system that may enhance alpha-casozepine's binding and functional activity. (Benoit et al., 2022)

This paradox illustrates how extraordinarily complex the GABAergic system is and why in vitro binding data alone cannot reliably predict in vivo pharmacological effects. It also highlights an honest reality: the underlying mechanism of alpha-casozepine remains incompletely understood, even as its clinical effects have been studied for over two decades.

A critical advantage over classical benzodiazepines

Unlike diazepam and related drugs, alpha-casozepine does not appear to produce dependence or habituation, meaning dogs do not develop tolerance requiring increasing doses, and there is no withdrawal risk associated with discontinuation. This distinguishes it meaningfully from prescription benzodiazepines and is one of the most clinically relevant aspects of its safety profile. (Benoit et al., 2022)

What the Clinical Evidence Shows in Dogs

The clinical evidence base for alpha-casozepine in dogs is growing but remains characterized by small sample sizes, variable study quality, and important methodological limitations that owners and clinicians should understand clearly.

Veterinary visits: a randomized placebo-controlled trial

The most methodologically rigorous published evidence for short-term use comes from Schroers et al. (2024), a randomized placebo-controlled trial conducted at Ludwig-Maximilians-Universität München. Dogs were administered oral casozepine for two days prior to a standardized veterinary examination (n=36 casozepine, n=26 placebo).

The results were mixed but partially positive. Dogs in the casozepine group showed significantly lower stress scores (p=0.0026) and lower mean (p=0.01) and maximum (p=0.024) pulse rates during the examination compared to placebo. Both were objective, measurable indicators of reduced physiological arousal. Salivary vasopressin, a stress hormone, remained stable in the casozepine group while increasing significantly in the placebo group (p=0.04). (Schroers et al., 2024)

However, the authors themselves described the effect as "weak." Both groups remained visibly excited during the examination. Salivary cortisol levels paradoxically increased in the casozepine group (p=0.01), a finding that complicates interpretation and was not fully explained. Only 22–31% of owners reported noticing significant changes in their dog's behavior, suggesting that while some physiological indicators shifted, the effect was not consistently apparent to owners in a home or clinical setting. (Schroers et al., 2024)

Multimodal calming blends: a crossover trial

Flint et al. (2025) conducted a blinded crossover study in 54 healthy adult dogs, testing four conditions: placebo, two doses of CBD alone (2 mg/kg and 4 mg/kg), and a blend of 2 mg/kg CBD combined with L-tryptophan and alpha-casozepine. Each dog received all four treatments in a randomized order, two hours before a 10-minute car travel stress paradigm designed to induce measurable stress responses.

Only one condition produced a statistically significant result: the combination of 2 mg/kg CBD with L-tryptophan and alpha-casozepine resulted in a significantly smaller increase in cortisol from baseline to post-stress compared to placebo (p=0.016). No other treatment produced significant effects across physiological or behavioral measures, although the blend group showed numerical trends toward less lip-licking and reduced activity. CBD plasma levels were highly variable between individual dogs, which the authors noted may have affected results. (Flint et al., 2025)

The isolation problem here is the same as with the melatonin Chill Protocol: alpha-casozepine was not studied in isolation. The specific contribution of alpha-casozepine to the cortisol reduction cannot be separated from the contributions of CBD and L-tryptophan. This is important context when interpreting the finding.

Metabolomic investigation: alpha-casozepine as a reference comparator

Roy et al. (2025) assigned 20 healthy Beagle dogs to four groups: placebo, Melissa officinalis extract, rosmarinic acid, and alpha-casozepine (225 mg Zylkene daily for 4 weeks). The primary purpose of the study was to investigate the mechanism of lemon balm extract, with alpha-casozepine serving as a known reference comparator. Behavior was monitored using a standardized evaluation grid, and 4-hydroxybutyric acid (a GABA pathway metabolite) was quantified as a biochemical marker of GABAergic system activity. (Roy et al., 2025)

The study documented behavioral score improvements and metabolic marker shifts in the alpha-casozepine group, consistent with its proposed GABAergic mechanism. This metabolomic approach provides novel mechanistic insight, showing that alpha-casozepine's activity in vivo is reflected in measurable changes in GABA pathway metabolites, though the very small group size (5 dogs per group) limits the strength of any conclusions drawn from this work. (Roy et al., 2025)

Separation-related disorders: open-label evidence

Porcheron et al. (2023) evaluated Zylkene Plus (alpha-casozepine combined with white fish muscle hydrolysate) in 47 dogs with separation-related disorders over 30 days. The results appeared striking: the percentage of dogs in a normal behavioral state increased from 26% at baseline to 62% at day 30. Specific behavioral problems showed the following improvements: excessive barking (48%), destructiveness (62%), inappropriate urination (72%), escaping (60%), and pacing. Quality of life improved by at least 30% in 74% of dogs. (Porcheron et al., 2023)

These numbers are impressive on the surface, but this study was open-label, multicenter, and non-blinded, with no placebo control group. Owner-reported outcomes in unblinded anxiety studies are particularly susceptible to caregiver placebo effect, the same phenomenon documented extensively in glucosamine and chondroitin research. Without a blinded placebo comparator, the magnitude of true pharmacological benefit cannot be separated from the expectation effect. This does not mean the results are wrong, but they require cautious interpretation and cannot be treated as equivalent to controlled trial data. (Porcheron et al., 2023)

Putting the Evidence in Context: What Does the Weight of Evidence Support?

Taken together, the published literature on alpha-casozepine in dogs suggests the following honest summary:

The mechanistic basis is well-characterized and plausible: GABAA benzodiazepine site binding has been confirmed, the in vivo pharmacological effect is established, and the absence of dependence and habituation is a genuine clinical advantage over prescription benzodiazepines. (Benoit et al., 2022)

The clinical effects in controlled trials are modest at best and difficult to pinpoint since it was commonly used as part of combination therapies. The best-controlled study, Schroers et al. 2024, found statistically significant reductions in stress scores and pulse rates, but characterized the overall effect as weak, with both groups remaining excited and a paradoxical cortisol increase in the treated group. (Schroers et al., 2024)

Alpha-casozepine shows more promise as a component of multimodal calming protocols than as a standalone agent. The Flint et al. 2025 finding that cortisol reduction was only significant in the CBD plus blend group, not in any single-ingredient group - supports its use alongside complementary compounds rather than in isolation. (Flint et al., 2025)

The most positive findings come from the least rigorous study designs. The open-label Porcheron data, while encouraging, is hypothesis-generating rather than confirmatory. (Porcheron et al., 2023)

Safety Profile and Practical Considerations

Alpha-casozepine has an excellent safety profile. It is classified as Generally Recognized As Safe (GRAS) by the FDA, has not been associated with significant adverse effects in published studies, does not cause the sedation or cognitive impairment associated with prescription benzodiazepines, and carries no dependence or withdrawal risk. It is derived from milk casein, so dogs with confirmed dairy protein allergies should avoid it, though this is a relatively uncommon clinical concern.

Unlike melatonin, there is no xylitol risk associated with Zylkene as a veterinary-formulated product. The supplement is available in capsule form, and the contents can be opened and mixed into food for dogs that resist taking capsules.

The manufacturer-recommended dosing for dogs is 15 mg/kg once daily. The Schroers study used two days of pre-visit administration; longer-term use of four weeks was used in the Roy metabolomics study. No pharmacokinetic data establishing the duration of action in dogs has been published, which means precise dosing recommendations remain empirical.

Where Alpha-Casozepine Fits in Clinical Practice

Alpha-casozepine is most appropriately positioned as a mild, safe, well-tolerated anxiolytic-like supplement for dogs with situational anxiety, particularly for veterinary visit stress, mild separation-related behavior, and noise sensitivity, where the goal is modest physiological calming rather than the pronounced sedation of prescription anxiolytics.

It is not a substitute for prescription behavioral medicine in dogs with severe anxiety, phobias, or compulsive disorders, where the weak effect size seen in controlled trials is unlikely to provide meaningful relief. In those cases, veterinary behavioral medicine, where combining pharmacological management (fluoxetine, trazodone, gabapentin, prescription benzodiazepines as appropriate) with structured behavioral modification, is indicated.

For dogs with mild situational anxiety, alpha-casozepine may be a reasonable adjunctive option, given the mild evidence of effect when used as part of a multi-modal regime. The evidence best supports its use starting several days before an anticipated stressor, consistent with the two-day pre-visit protocol of Schroers et al. However, any use should be under the guidance or advice of a veterinarian.

Final Thoughts

Alpha-casozepine has a genuinely interesting and reasonably well-characterized mechanism of action, a favorable safety profile, and a growing evidence base that spans laboratory pharmacology, controlled clinical trials, and observational studies. The honest summary of where the science currently stands is that it produces real but modest effects in the most rigorous trials, shows greater promise in multimodal combinations, and has the most impressive-appearing results in the least controlled study designs.

For a mild, safe, non-prescription calming supplement with a plausible mechanism, no published dependence risk, and acceptable controlled trial data, alpha-casozepine may be a reasonable option to achieve a mild calming effect, particularly as part of a broader anxiety management plan developed with veterinary guidance. It is not a replacement for behavioral medicine, and its standalone effect should not be overstated.